Stocktoria
Arcutis Biotherapeutics, Inc. ARQT
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-01-31
Arcutis Biotherapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $376.1M | $196.5M | $59.6M | $3.7M | $0 | $0 | — |
| R&D expense | $77.1M | $76.4M | $110.6M | $182.4M | $145.6M | $115.3M | $36.5M |
| SG&A expense | $274.6M | $229.4M | $185.1M | $122.1M | $61.0M | — | — |
| Operating income | -$12.2M | -$128.4M | -$241.1M | -$301.6M | -$206.5M | -$136.6M | -$43.1M |
| Interest expense | — | — | $29.7M | $15.7M | $0 | $0 | — |
| Income tax | $1.2M | $647,000 | $3.1M | $0 | $0 | $0 | $0 |
| Net income | -$16.1M | -$140.0M | -$262.1M | -$311.5M | -$206.4M | -$135.7M | -$42.0M |
| EPS (diluted) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 | $-22.78 |
| Operating cash flow | -$5.6M | -$112.2M | -$247.1M | -$257.7M | -$174.6M | -$113.0M | -$42.8M |
| Free cash flow | -$6.3M | -$112.3M | -$247.5M | -$258.0M | -$175.6M | -$113.4M | -$43.1M |
| Cash & equivalents | $42.9M | $71.3M | $88.4M | $53.6M | $96.4M | $65.1M | $63.3M |
| Inventory | $22.6M | $14.5M | $13.1M | $7.5M | $0 | — | — |
| Total assets | $433.0M | $348.9M | $341.4M | $449.3M | $408.2M | $298.3M | $107.0M |
| Total liabilities | $243.5M | $191.3M | $252.7M | $239.7M | $110.5M | $27.6M | $5.5M |
| Shareholders' equity | $189.5M | $157.5M | $88.7M | $209.6M | $297.7M | $270.6M | -$65.0M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +91.3% | +229.7% | +1517.1% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.